{"transactions":[{"id":4627008,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The canceled option provided for vesting in 4 equal installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627007,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":10.4,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627006,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The canceled option provided for vesting in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022."}],"balance_after":0,"derivative":{"exercise_price":8.14,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627005,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":69999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled option provided for vesting in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019."}],"balance_after":0,"derivative":{"exercise_price":7.77,"expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":69999},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627004,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.8,"expiration_date":"2030-01-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627003,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":104000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The canceled option provided for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":3.16,"expiration_date":"2029-09-11","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627002,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":209291,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the \"Plan\"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan."}],"balance_after":1550554,"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":4627001,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-25T20:30:59.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":208125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors."}],"balance_after":1341263,"source":{"system":"sec-edgar","filing":"0001213900-26-103536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000121390026103536/ownership.xml","form_type":"4"}},{"id":824441,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-31T20:10:28.000Z","date":"2026-03-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":435084,"price":3.31,"value":1440128.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share."}],"balance_after":1133138,"source":{"system":"sec-edgar","filing":"0001213900-26-037446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026037446/ownership.xml","form_type":"4"}},{"id":826287,"issuer":{"id":7620,"kind":"organization","name":"Lifeward Ltd.","symbol":"LFWD"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, no par value per share","published_at":"2026-03-27T20:37:30.000Z","date":"2026-03-25","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units (\"RSUs\") granted on March 25, 2026 (the \"Grant Date\") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date."}],"balance_after":7657,"source":{"system":"sec-edgar","filing":"0001178913-26-001812","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1409232/000117891326001812/ownership.xml","form_type":"4"}},{"id":835482,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:46:58.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":119558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer."}],"balance_after":1568222,"source":{"system":"sec-edgar","filing":"0001213900-26-031015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026031015/ownership.xml","form_type":"4"}},{"id":928070,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-29T21:05:33.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-009478","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009478/ownership.xml","form_type":"4"}},{"id":928069,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-29T21:05:33.000Z","date":"2026-01-22","kind":"exercise","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share (\"Common Stock\"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting."}],"balance_after":1448664,"source":{"system":"sec-edgar","filing":"0001213900-26-009478","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026009478/ownership.xml","form_type":"4"}},{"id":934482,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-21T21:30:02.000Z","date":"2026-01-14","kind":"gift","planned":false,"acquired":false,"shares":86166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee."}],"balance_after":1343498,"source":{"system":"sec-edgar","filing":"0001213900-26-006215","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026006215/ownership.xml","form_type":"4"}},{"id":952498,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-05T22:21:03.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria."}],"balance_after":19000,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001213900-26-001279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001279/ownership.xml","form_type":"4"}},{"id":952497,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T22:21:03.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer."}],"balance_after":1429664,"source":{"system":"sec-edgar","filing":"0001213900-26-001279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001279/ownership.xml","form_type":"4"}},{"id":952496,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T22:21:03.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":121331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share (\"Common Stock\"), of the Issuer."}],"balance_after":1314664,"source":{"system":"sec-edgar","filing":"0001213900-26-001279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390026001279/ownership.xml","form_type":"4"}},{"id":1274396,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:37.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":66667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares issued on settlement of PSUs previously granted on February 3, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":1193333,"source":{"system":"sec-edgar","filing":"0001213900-25-012241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012241/ownership.xml","form_type":"4"}},{"id":1274395,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:37.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":1126666,"source":{"system":"sec-edgar","filing":"0001213900-25-012241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012241/ownership.xml","form_type":"4"}},{"id":1274394,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-11T21:31:37.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":74000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of performance stock units (\"PSUs\") previously granted on January 4, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria."}],"balance_after":1074666,"source":{"system":"sec-edgar","filing":"0001213900-25-012241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012241/ownership.xml","form_type":"4"}},{"id":1311339,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:10:09.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":207000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in quarterly installments of approximately 17,250 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":1000666,"source":{"system":"sec-edgar","filing":"0001213900-25-001169","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025001169/ownership.xml","form_type":"4"}},{"id":1371697,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-11-08T21:30:23.000Z","date":"2024-11-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":793666,"source":{"system":"sec-edgar","filing":"0001213900-24-095930","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024095930/ownership.xml","form_type":"4"}},{"id":1684523,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:43:05.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":295500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in equal quarterly installments of 24,625 over a three year period starting January 8, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":763666,"source":{"system":"sec-edgar","filing":"0001209191-24-001154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919124001154/doc4.xml","form_type":"4"}},{"id":1873527,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-05-31T21:10:16.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":53500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") granted in April 2023 and vested upon achievement of certain performance conditions. The RSUs converted into Issuer's common stock on a one-for-one basis."}],"balance_after":468166,"source":{"system":"sec-edgar","filing":"0001209191-23-033143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919123033143/doc4.xml","form_type":"4"}},{"id":1916597,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-04-20T10:00:17.000Z","date":"2023-04-17","kind":"grant","planned":false,"acquired":true,"shares":213000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in equal quarterly installments of 17,750 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":414666,"source":{"system":"sec-edgar","filing":"0001209191-23-024937","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919123024937/doc4.xml","form_type":"4"}},{"id":1952537,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-15T21:20:08.000Z","date":"2023-03-14","kind":"sale","acquired":false,"shares":100000,"price":2.01,"value":201000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were sold to a company owned solely by Nadav Kidron, a director and the president and chief executive officer of the Issuer, and  the Reporting Person used the proceeds in connection with a personal tax payment."}],"balance_after":201666,"source":{"system":"sec-edgar","filing":"0001209191-23-018952","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919123018952/doc4.xml","form_type":"4"}},{"id":2199217,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-02T00:00:54.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":84000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in 3 installments as follows: 28,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":301666,"source":{"system":"sec-edgar","filing":"0001209191-22-043769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919122043769/doc4.xml","form_type":"4"}},{"id":2199216,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-02T00:00:54.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":34000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Stock granted by the Issuer that vested on August 1, 2022."}],"balance_after":217666,"source":{"system":"sec-edgar","filing":"0001209191-22-043769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000120919122043769/doc4.xml","form_type":"4"}},{"id":2444635,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T01:39:39.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option will vest in 4 installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026."}],"balance_after":72000,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001213900-22-000816","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022000816/ownership.xml","form_type":"4"}},{"id":2444634,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-06T01:39:39.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":42000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in 4 installments as follows: 10,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":183666,"source":{"system":"sec-edgar","filing":"0001213900-22-000816","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022000816/ownership.xml","form_type":"4"}},{"id":2582052,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-02T20:46:50.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (\"RSUs\") granted in February 2021 and vested upon achievement of certain vesting conditions. The RSUs convert into Issuer's common stock on a one-for-one basis."}],"balance_after":141666,"source":{"system":"sec-edgar","filing":"0001213900-21-046411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390021046411/ownership.xml","form_type":"4"}},{"id":2874788,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-08T22:31:37.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Stock Option will vest in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024."}],"balance_after":100000,"derivative":{"exercise_price":10.4,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-21-007501","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390021007501/ownership.xml","form_type":"4"}},{"id":3311775,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-14T21:05:04.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in 4 installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023."}],"balance_after":100000,"derivative":{"exercise_price":4.8,"expiration_date":"2030-01-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-20-000985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390020000985/ownership.xml","form_type":"4"}},{"id":3414029,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-09-16T22:07:03.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":104000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":104000,"derivative":{"exercise_price":3.16,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001213900-19-018198","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390019018198/ownership.xml","form_type":"4"}},{"id":3414028,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-09-16T22:07:03.000Z","date":"2019-02-26","kind":"disposition_to_issuer","acquired":false,"shares":104000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":3.16,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001213900-19-018198","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390019018198/ownership.xml","form_type":"4"}},{"id":3626583,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-28T21:57:09.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":104000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022."}],"balance_after":104000,"derivative":{"exercise_price":3.16,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001213900-19-003337","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390019003337/ownership.xml","form_type":"4"}},{"id":4079461,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-02T22:32:42.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022."}],"balance_after":47000,"derivative":{"exercise_price":8.14,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-18-001245","document":"f4013118kidronmiriam_oramed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390018001245/f4013118kidronmiriam_oramed.xml","form_type":"4"}},{"id":4243829,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-08-03T22:00:26.000Z","date":"2017-08-02","kind":"sale","acquired":false,"shares":89636,"price":8.5,"value":761906.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold to Li Xiaopeng, a director of Oramed Pharmaceuticals Inc., and the reporting person used the proceeds in connection with a personal tax payment."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 75,000 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001213900-17-008213","document":"f4080217kidron_oramed.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390017008213/f4080217kidron_oramed.xml","form_type":"4"}},{"id":4264859,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-07-05T19:38:54.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":69999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Stock Option will vest in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019."}],"balance_after":69999,"derivative":{"exercise_price":7.77,"expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":69999},"source":{"system":"sec-edgar","filing":"0001213900-17-007158","document":"f4063017mkidron_oramed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390017007158/f4063017mkidron_oramed.xml","form_type":"4"}},{"id":4264858,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-07-05T19:38:54.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest immediately."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 164,636 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request."}],"balance_after":164636,"source":{"system":"sec-edgar","filing":"0001213900-17-007158","document":"f4063017mkidron_oramed.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390017007158/f4063017mkidron_oramed.xml","form_type":"4"}},{"id":4349835,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":55146,"kind":"person","name":"Kidron Miriam","position":1,"cik":"0001409232","reported_name":"Kidron Miriam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-04-19T21:01:07.000Z","date":"2017-04-19","kind":"sale","acquired":false,"shares":52814,"price":6.33,"value":334312.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold to Li Xiapeng, a director of Oramed Pharmaceuticals Inc."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 89,636 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request."}],"balance_after":89636,"source":{"system":"sec-edgar","filing":"0001178913-17-001170","document":"zk1719828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000117891317001170/zk1719828.xml","form_type":"4"}}]}